Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1

Autor: C Cheneau, S Barthier, J Lemonnier, Fabrice Andre, C Dubot, L Teixeira, A Escande, T De La Motte Rouge, T Petit, L Arnould, Laurent Arnould, Suzette Delaloge, Jerome Lemonnier, A Marti, L Stefani, F Berger, C Levy, P Barthelemy, S Nguyen, M Gardner, A Lortholary, François-Clément Bidard, J Plaza, L Joly, Thibault de la Motte Rouge, F Andre, I Bièche, C Alleaume, R Sabatier, B Lucas, Ivan Bieche, O Derbel, L Venat-Bouvet, F Del Piano, Florian Clatot, Anne-Claire Hardy-Bessard, Frédérique Berger, Margaux Marce, Thomas Bachelot, Anne Pradines, Jean-Luc Canon, Sandrine Marques, M Achille, H Ammarguellat, O Arsene, T Bachelot, C Bernard-Marty, F-C Bidard, N Bonichon-Lamichhane, N Bonnin, R Bouaita, A Boudrant, V-A Brunel, C Chakiba, F Clatot, F Dalenc, A De Gramont, L Deiana, C Delbaldo, V Delecroix, H Desclos, V D'Hondt, N Dohollou, J-M Ferrero, C Foa, J-S Frenel, C Garnier Tixidre, D Genet, O Gisserot, M Gozy, C Greilsamer, J Grenier, F Guinet, A-C Hardy-Bessard, J-P Jacquin, E Lachaier, S Ladoire, A-P Laurenty, R Le Scodan, N Leduc, E Legouffe, C Levache, F Lorchel, N Marques, J Medioni, A Melis, D Mille, D Mollon, L Moreau, I Moullet, M-A Mouret-Reynier, A Najem, H Orfeuvre, J-F Paitel, B Pistilli, C Riedl, P Soulie, D Spaeth, F Trouboul, C Valmar, H Vegas, A Zannetti, FC Bidard, S Delaloge, A Pradines, JL Canon, S Marques

Publikováno v: BMJ Open, Vol 12, Iss 3 (2022)

Introduction The combination of a CDK4/6 inhibitor with an aromatase inhibitor (AI) has recently become the gold standard for AI-sensitive first line treatment of oestrogen receptor-positive (ER+) HER2-negative (HER2−) advanced breast cancer. Howev

Externí odkaz: https://doaj.org/article/8faf6bbc845f4ceeb90674dd08e198da

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

59P Expression of CD47 a potent ‘don’t eat me signal' in ovarian cancer (OC): Correlation with other immune features and evolution under neoadjuvant chemotherapy (NACT), a GINEGEPS study

Autor: L. Chardin, E. Yaniz Galende, C. Genestie, A. Le Formal, C. Schneider, A. Jeanne, L. Venat-Bouvet, C. Louvet, L. Favier, A. Lortholary, D. Berton-Rigaud, N. Dohollou, C. Desauw, M. Fabbro, E. Malaurie, C. Dubot, J.E. Kurtz, N. Bonichon Lamichhane, S. Dedieu, A. Leary

Publikováno v: ESMO Open. 8:100839

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8223e20ecf53485a0d534ee5733c724a
https://doi.org/10.1016/j.esmoop.2023.100839

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial

Autor: Giovanni Scambia, Daniela Sambataro, Coraline Dubot, Rossella Lauria, Francesco Raspagliesi, Patricia Pautier, Simona Frezzini, S Mammoliti, U De Giorgi, Ugo De Giorgi, C Sessa, Angiolo Gadducci, Isabelle Ray-Coquard, A Gadducci, Rémy Largillier, Francesco Perrone, Alessandra Bologna, Sandro Pignata, G Scambia, Elena Zafarana, E Breda, Florence Joly, R Largillier, Saverio Cinieri, C Pisano, Carmela Pisano, C Gallo, Frédéric Selle, Vanda Salutari, Cristiana Sessa, Aristotelis Bamias, F Joly, R Lauria, A Ardizzoia, Laure Favier, Nicoletta Colombo, D Sambataro, F Perrone, Domenica Lorusso, C Dubot, G Daniele, Emmanuel Guardiola, A Bamias, Gennaro Daniele, V Salutari, F Selle, S. Mammoliti, E Zafarana, P Pautier, M Orditura, Enrico Breda, A Bologna, E Guardiola, Michele Orditura, Ciro Gallo, L Favier, S Cinieri, N Colombo, I Ray-Coquard, S Frezzini, S Pignata, F Raspagliesi, Antonio Ardizzoia

Background: Bevacizumab is approved in combination with chemotherapy for the treatment of ovarian cancer, either in first-line therapy or for patients with recurrent disease not previously treated with the same drug. We aimed to test the value of con

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e5cf8324eaa8e8e6577f2c091ed2f66
http://hdl.handle.net/11591/461646